Slingshot members are tracking this event:
Baxalta Commences Phase 1 Clinical Trial of BAX 826, the Company’s Second Extended Half-Life Factor VIII Treatment for Hemophilia A
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
BAX 826 is a next-generation rFVIII treatment based on the full length ADVATE. The compound is modified using proprietary polysialic acid (PSA) technology licensed from Xenetic Biosciences, Inc. (OTCQB: XBIO) to extend its circulating half-life. Baxalta has partnered with Xenetic to develop novel forms of polysialylated blood coagulation factors, including FVIII. Xenetic’s PolyXen™ technology utilizes the biopolymer PSA in order to extend the circulating half-life and potentially improve the pharmacokinetic profile of therapeutic proteins, peptides, and small molecules. Preclinical studies indicated BAX 826 offered an extended circulating half-life compared to standard rFVIII.
Slingshot Insights Explained
Mar 04, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Bax 826, Half-life Factor Viii Treatment, Hemophilia A, Phase 1